GLP-1 agonists, often used to manage diabetes and obesity, may influence pregnancy outcomes when used during gestation. These drugs can cross the placenta, potentially affecting fetal development, particularly in cases of maternal obesity or type 2 diabetes. Consultation with a healthcare provider is essential for expectant mothers on these medications, as they should weigh potential risks against benefits, considering alternatives like metformin for gestational diabetes management. This discussion ensures informed decision-making to safeguard both maternal and fetal health. | #souvenirs
Respect!
Kommentar
Delen
